Trials / Completed
CompletedNCT03112694
Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors
A Multicenter, Retrospective, Medical Record Review Of The Effectiveness Of Lanreotide Following Treatment With Octreotide In Patients With Neuroendocrine Tumors
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 93 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to understand how people with neuroendocrine tumors respond to treatment with lanreotide after having received treatment with octreotide.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Data collection | This is a non-interventional study, the decision to prescribe the product would have been taken prior to, and independently from the decision to enrol the patient. |
Timeline
- Start date
- 2017-04-04
- Primary completion
- 2017-11-02
- Completion
- 2017-11-02
- First posted
- 2017-04-13
- Last updated
- 2020-06-02
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT03112694. Inclusion in this directory is not an endorsement.